Sep 12 2012
e-Therapeutics plc (AIM: ETX) announces that it has started a second
phase I clinical trial of its anti-cancer drug ETS2101. This trial will
enrol up to 45 patients with a variety of solid tumours at two UK
centres, St James's University Hospital in Leeds and the Northern Centre
for Cancer Care at the Freeman Hospital in Newcastle. It complements an
investigator-led phase I study of ETS2101 in brain cancer that began in
San Diego, California during June.
Like the brain cancer study, the UK trial has a dose-escalating design
in which groups of patients receive successively higher doses of the
drug. The primary objective is to evaluate the safety of ETS2101 and
identify an appropriate dose for phase II development. Secondary
objectives include initial assessment of the drug's activity and
evaluation of its distribution within the body (pharmacokinetics). Final
results from the trial are expected during 2013.
Professor Ruth Plummer, Clinical Professor of Experimental Cancer
Medicine at the Northern Institute for Cancer Research and lead
investigator for the phase I study at the Freeman Hospital, Newcastle,
said: "ETS2101 derives from an interesting new approach to drug
discovery known as network pharmacology. We are pleased to be involved
in the first phase of clinical trials evaluating this drug as a
potential treatment for cancer."
e-Therapeutics' CEO, Professor Malcolm Young, added: "The initiation of
a second trial with ETS2101 reflects the growing momentum in our
clinical development programme. We hope that the promising preclinical
data supporting this drug will ultimately translate into benefits for
patients and look forward to seeing the first findings from cancer
trials later this year."
FTC, Indiana residents pressure state to block hospital merger